S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
Log in

NASDAQ:DRNA - Dicerna Pharmaceuticals Stock Price, Forecast & News

$20.44
-0.38 (-1.83 %)
(As of 02/24/2020 04:00 PM ET)
Today's Range
$20.04
Now: $20.44
$20.92
50-Day Range
$18.94
MA: $20.66
$22.60
52-Week Range
$10.38
Now: $20.44
$27.68
Volume525,800 shs
Average Volume633,969 shs
Market Capitalization$1.40 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.63
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DRNA
CUSIPN/A
Phone617-621-8097

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.18 million
Book Value$3.20 per share

Profitability

Net Income$-88,850,000.00
Net Margins-541.24%

Miscellaneous

Employees78
Market Cap$1.40 billion
Next Earnings Date2/27/2020 (Confirmed)
OptionableOptionable

Receive DRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for DRNA and its competitors with MarketBeat's FREE daily newsletter.


Dicerna Pharmaceuticals (NASDAQ:DRNA) Frequently Asked Questions

What is Dicerna Pharmaceuticals' stock symbol?

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

How were Dicerna Pharmaceuticals' earnings last quarter?

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) released its quarterly earnings data on Thursday, November, 7th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.15. The biopharmaceutical company had revenue of $8.04 million for the quarter, compared to analyst estimates of $11.70 million. Dicerna Pharmaceuticals had a negative net margin of 541.24% and a negative return on equity of 58.92%. View Dicerna Pharmaceuticals' Earnings History.

When is Dicerna Pharmaceuticals' next earnings date?

Dicerna Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Dicerna Pharmaceuticals.

How can I listen to Dicerna Pharmaceuticals' earnings call?

Dicerna Pharmaceuticals will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for DRNA?

8 brokerages have issued 1 year price objectives for Dicerna Pharmaceuticals' stock. Their forecasts range from $18.00 to $50.00. On average, they anticipate Dicerna Pharmaceuticals' stock price to reach $31.57 in the next year. This suggests a possible upside of 54.5% from the stock's current price. View Analyst Price Targets for Dicerna Pharmaceuticals.

What is the consensus analysts' recommendation for Dicerna Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dicerna Pharmaceuticals.

Has Dicerna Pharmaceuticals been receiving favorable news coverage?

News stories about DRNA stock have been trending neutral on Monday, InfoTrie Sentiment reports. The research group scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Dicerna Pharmaceuticals earned a news impact score of 0.4 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Dicerna Pharmaceuticals.

Are investors shorting Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals saw a increase in short interest in January. As of January 31st, there was short interest totalling 2,840,000 shares, an increase of 6.4% from the January 15th total of 2,670,000 shares. Based on an average trading volume of 925,400 shares, the days-to-cover ratio is currently 3.1 days. Currently, 5.1% of the shares of the stock are short sold. View Dicerna Pharmaceuticals' Current Options Chain.

Who are some of Dicerna Pharmaceuticals' key competitors?

What other stocks do shareholders of Dicerna Pharmaceuticals own?

Who are Dicerna Pharmaceuticals' key executives?

Dicerna Pharmaceuticals' management team includes the folowing people:
  • Dr. Douglas M. Fambrough III, Co-Founder, CEO, Pres & Director (Age 50)
  • Dr. Bob D. Brown, Chief Scientific Officer & Sr. VP (Age 54)
  • Dr. Ralf H. Rosskamp, Chief Medical Officer (Age 66)
  • Dr. Mark Behlke, Co-Founder & Member of Scientific Advisory Board
  • Prof. John J. Rossi, Co-Founder & Chairman of Scientific Advisory Board (Age 72)

Who are Dicerna Pharmaceuticals' major shareholders?

Dicerna Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Bain Capital Life Sciences Investors LLC (5.96%), EcoR1 Capital LLC (5.30%), UBS Group AG (3.20%), Bridger Management LLC (2.90%), Eagle Asset Management Inc. (2.57%) and State Street Corp (2.42%). Company insiders that own Dicerna Pharmaceuticals stock include Adam Koppel, Bain Capital Life Sciences Inv, Bob D Brown, Brian K Halak, Dennis Langer, Douglas Fambrough, James B Weissman, John B Green and Peter Kolchinsky. View Institutional Ownership Trends for Dicerna Pharmaceuticals.

Which major investors are selling Dicerna Pharmaceuticals stock?

DRNA stock was sold by a variety of institutional investors in the last quarter, including Bain Capital Life Sciences Investors LLC, Bridger Management LLC, EcoR1 Capital LLC, UBS Group AG, Sofinnova Investments Inc., Emerald Advisers LLC, State Street Corp and Emerald Mutual Fund Advisers Trust. Company insiders that have sold Dicerna Pharmaceuticals company stock in the last year include Adam Koppel, Bain Capital Life Sciences Inv, Bob D Brown, Douglas Fambrough, James B Weissman, John B Green and Peter Kolchinsky. View Insider Buying and Selling for Dicerna Pharmaceuticals.

Which major investors are buying Dicerna Pharmaceuticals stock?

DRNA stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Driehaus Capital Management LLC, Marshall Wace LLP, Renaissance Technologies LLC, Parkman Healthcare Partners LLC, Marshall Wace North America L.P., Connor Clark & Lunn Investment Management Ltd. and EAM Investors LLC. View Insider Buying and Selling for Dicerna Pharmaceuticals.

How do I buy shares of Dicerna Pharmaceuticals?

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Dicerna Pharmaceuticals' stock price today?

One share of DRNA stock can currently be purchased for approximately $20.44.

How big of a company is Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals has a market capitalization of $1.40 billion and generates $6.18 million in revenue each year. The biopharmaceutical company earns $-88,850,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Dicerna Pharmaceuticals employs 78 workers across the globe.View Additional Information About Dicerna Pharmaceuticals.

What is Dicerna Pharmaceuticals' official website?

The official website for Dicerna Pharmaceuticals is http://www.dicerna.com/.

How can I contact Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals' mailing address is 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA, 02140. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]


MarketBeat Community Rating for Dicerna Pharmaceuticals (NASDAQ DRNA)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  387 (Vote Outperform)
Underperform Votes:  271 (Vote Underperform)
Total Votes:  658
MarketBeat's community ratings are surveys of what our community members think about Dicerna Pharmaceuticals and other stocks. Vote "Outperform" if you believe DRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel